Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.06-6.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VERU
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Phase 2b PLATEAU clinical trial is fully enrolled, and we expect the interim analysis, a near term milestone, in calendar Q1 2027.
Stated in 2 of 2 supplied quarters. Management reported: “During the past quarter, the Company exceeded its Phase 2b PLATEAU clinical trial targeted full enrollment of 200 patients by enrolling 239 patients.” “Results of an interim analysis assessing lean body mass and fat mass as measured by DXA after patients have completed 32 weeks is expected in the first quarter of calendar year 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“During the past quarter, the Company exceeded its Phase 2b PLATEAU clinical trial targeted full enrollment of 200 patients by enrolling 239 patients.”
“We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru I…”
We entered into a clinical supply agreement with Novo Nordisk 2 , and we now have an issued US patent for enobosarm with semaglutide with expiry in late 2044.”
Stated in 1 of 2 supplied quarters. Management reported: “When issued, this U.S. patent will have a patent expiry of at least October 3, 2044, prior to the potential application of any patent term adjustment or patent term extension.” “These allowed claims add to the Company’s growing intellectual property portfolio for enobosarm for quality weight loss, including already issued enobosarm specific polymorph composition of matter patents, as well as a number of other pending uses of selective androgen receptor modulator compounds alone or in combination with weight loss drugs for quality weight loss and chronic weight management patent applications.”
“When issued, this U.S. patent will have a patent expiry of at least October 3, 2044, prior to the potential application of any patent term adjustment or patent term extension.”
The Company continues to prosecute a number of pending patent applications worldwide covering a number of different weight loss drugs beyond semaglutide.
Stated in 2 of 2 supplied quarters. Management reported: “The Company continues to prosecute a number of pending patent applications worldwide covering a number of different weight loss drugs beyond semaglutide.” “The Company continues to prosecute a number of pending patent applications worldwide covering a number of different weight loss drugs beyond semaglutide.”
“The Company continues to prosecute a number of pending patent applications worldwide covering a number of different weight loss drugs beyond semaglutide.”
“Second Quarter Financial Summary: Fiscal 2026 vs Fiscal 2025 • Research and development expenses decreased to $3.1 million from $3.9 million • General and administrative expenses decreased to $4.1 mi…”
With the goal of maximizing Veru shareholder value, we have made the strategic decision to advance sabizabulin into a Phase 2b clinical trial.
Stated in a supplied disclosure. Management reported: “With the goal of maximizing Veru shareholder value, we have made the strategic decision to advance sabizabulin into a Phase 2b clinical trial.” “We will first seek regulatory clarity from the FDA through a preIND meeting in calendar Q4 2026 to better understand the scope of the clinical trial.”
Manage capital through agreements such as clinical supply contracts and debt issuance to support clinical development and operations.
Over the trailing year it converted 1.08x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.